|
WO2020079630A1
|
|
New uses of a 5-ht4 receptor agonist
|
|
WO2020079606A1
|
|
Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
|
|
KR20200090854A
|
|
Azacycle substituted as muscarinic M1 receptor positive allosteric modulator
|
|
CN111278814A
|
|
Polycyclic amides as positive allosteric modulators of the muscarinic M1 receptor
|
|
CN111212840A
|
|
Heteroaryl compounds as positive allosteric modulators of the muscarinic M1 receptor
|
|
WO2019058290A1
|
|
Improved process for the preparation of ozanimod α-amino compound
|
|
SG11202000833YA
|
|
Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
|
|
AU2018425507A1
|
|
Method of treatment with histamine-3 receptor inverse agonist
|
|
CA3067929A1
|
|
New uses of a pure 5-ht6 receptor antagonist
|
|
BR112019006588A2
|
|
immediate release pharmaceutical composition
|
|
EP3507289A1
|
|
Muscarinic m1 receptor positive allosteric modulators
|
|
EA035599B1
|
|
Muscarinic m1 receptor positive allosteric modulators
|
|
NZ750121A
|
|
Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist
|
|
CA3033039A1
|
|
Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
|
|
CN109069390A
|
|
The external application spray formulation of glycopyrronium bromide
|
|
CN109069449A
|
|
Pure 5-HT6The combination of receptor antagonist and nmda receptor antagonist
|
|
MA45639B1
|
|
Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
|
|
MA45002B1
|
|
Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonists
|
|
CN108026073A
|
|
Fluoroindole derivatives as muscarinic M 1 receptor forward direction allosteric modulators
|
|
RS58665B1
|
|
Muscarinic m1 receptor positive allosteric modulators
|
